Leo Pharma starts phase III hand eczema trial

Leo Pharma will test the effectivity of its treatment delgocitinib in treating chronic hand eczema in a phase III trial. It has high hopes for the indication.
Photo: Leo Pharma / PR
Photo: Leo Pharma / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT

After a positive phase II study, Leo Pharma has moved onto phase III trials for its eczema treatment delgocitinib. The first patients have been enrolled in the trial.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading